Provided by Tiger Trade Technology Pte. Ltd.

Prelude Therapeutics Inc

4.38
+0.28006.83%
Post-market: 4.30-0.0800-1.83%16:34 EDT
Volume:3.69M
Turnover:16.09M
Market Cap:348.84M
PE:-4.42
High:4.38
Open:4.08
Low:4.02
Close:4.10
52wk High:5.54
52wk Low:0.7500
Shares:79.64M
Float Shares:8.06M
Volume Ratio:7.58
T/O Rate:45.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9899
EPS(LYR):-1.2929
ROE:-95.25%
ROA:-39.69%
PB:5.80
PE(LYR):-3.39

Loading ...

Prelude Therapeutics Shareholders Back Leadership and Governance

TIPRANKS
·
Jun 11

Prelude Therapeutics shareholders elect three directors at annual meeting

Reuters
·
Jun 11

Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

TIPRANKS
·
May 15

Prelude Therapeutics (PRLD) Losses Narrow In Q1 2026 Challenging Bearish Narratives

Simply Wall St.
·
May 14

Prelude Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)

TIPRANKS
·
May 12

Prelude Therapeutics Q1 EPS $(0.13) Beats $(0.25) Estimate, Sales $4.580M

Benzinga
·
May 12

Prelude Therapeutics Q1 net loss narrows as expenses fall

Reuters
·
May 12

BRIEF-Prelude Therapeutics Q1 EPS USD -0.13

Reuters
·
May 12

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 12

Prelude Therapeutics Q1 Operating Expenses USD 18.757 Million

THOMSON REUTERS
·
May 12

Prelude Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
May 08

Prelude Therapeutics Initiated at Buy by D. Boral Capital

Dow Jones
·
May 04

Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers

TIPRANKS
·
May 03

Prelude Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
May 01

Prelude Therapeutics initial beneficial ownership statement names RA Capital Management

Reuters
·
Apr 29

Prelude Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 27

Prelude Therapeutics Incorporated : H.c. Wainwright Raises Target Price to $8 From $5

THOMSON REUTERS
·
Apr 27

Massive Insider Buying Spree Signals Bold Confidence in Prelude Therapeutics

TIPRANKS
·
Apr 24

OrbiMed Advisors acquires $12.5 million Prelude Therapeutics common shares

Reuters
·
Apr 24